Directing B7-H3 chimeric antigen receptor T cell homing through IL-8 induces potent antitumor activity against pediatric sarcoma.
Jessica A LakeElena WoodsEric HoffmeyerKristin L SchallerJoselyn Cruz-CruzJoseph FernandezDejene TufaBenjamin KooimanSpencer C HallDallas JonesMasanori HayashiMichael R VernerisPublished in: Journal for immunotherapy of cancer (2024)
These findings warrant further investigation into the use of BC2 CAR T cells as a treatment for patients with RMS, OS and other B7-H3-expressing, IL-8 producing solid tumors.
Keyphrases